LLY

-33.69 (-3.67%)

Eli Lilly and Company

HealthcareNYSEMCap: $835.18B
$883.96Website
52-Week Range51% of range
$623.78$1,133.95
Dec 24Mar 25May 25Aug 25Nov 25Jan 26Apr 26$600$750$900$1050$1200

About

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Key Metrics

Market Cap
$965.06B
P/E Ratio
0
P/B Ratio
0
EV/EBITDA
35.81
ROE
77.78%
Dividend Yield
0.00%
Debt/Equity
0
Current Ratio
1.58
EV
$1.00T
Earnings Yield
2.14%
FCF Yield
0.93%
ROIC
30.20%

Revenue & Net Income

2016201720182019202020212022202320242025-$25.00B$0.00$25.00B$50.00B$75.00B

Profit Margins

2016201720182019202020212022202320242025-30.0%0.0%30.0%60.0%90.0%

Cash Flow

2016201720182019202020212022202320242025-$8.50B$0.00$8.50B$17.00B$25.50B

EPS (Diluted)

2016201720182019202020212022202320242025$-8.00$0.00$8.00$16.00$24.00

Company Info

CEO
David A. Ricks
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
Country
US
Employees
47000
IPO Date
1972-06-01
52W Range
623.78-1133.95
www.lilly.com
Sponsored

Robo-Advisory Platform

Automated portfolio management

Let algorithms manage your portfolio with tax-loss harvesting and automatic rebalancing.

Start Investing